Biopharmaceutical partners
Translate a differentiated immune-support platform into indication-led development programs.
- Licensing strategy
- Co-development
- Adjunctive therapy evaluation
Priority programs · ARDS / Oncology
Cellular immune support, precisely advanced.
ImmunoFolate™ is Rapid Defense Inc.’s patented nutraceutical platform for evidence-led investigation across high-unmet-need indications, beginning with ARDS and Oncology.
Executive agency preview. Scientific imagery and supporting materials shown are directional placeholders pending Rapid Defense approval.
IF–01Patented platformCellular research thesis
ProprietaryPatent-protected IP
02Priority indications
PhD-ledScientific foundation
ActiveInstitutional partnerships
Mechanism of action
A cellular thesis built for disciplined validation.
Explore the three interconnected research pillars shaping ImmunoFolate’s translational development strategy.
Directional scientific visualization · Pending approvalTarget recognition
Folate receptor affinity
The platform hypothesis begins with selective affinity at folate receptor interfaces associated with activated immune environments.
Indication explorer
Focused where clinical need is most consequential.
IF–ARDS
Acute Respiratory Distress Syndrome
A critical-care setting where rapid inflammatory escalation and compromised pulmonary barriers create an urgent need for complementary strategies.
01 / Clinical rationale
Investigate support for immune-cell function and mucosal resilience in high-stress respiratory environments.
02 / Unmet need
ARDS continues to carry substantial morbidity, mortality, and intensive-care burden across heterogeneous causes.
03 / Adjunctive potential
A potential adjunctive pathway designed for investigation alongside established standards of care—not as a replacement.
Scientific rationale is presented for partnership discussion only. ImmunoFolate™ is not represented here as approved to diagnose, treat, cure, or prevent disease.
Development pipeline
Evidence milestones, clearly delineated.
Translational infrastructureFrom protected formulation to institutional co-development.Directional laboratory visualization · Pending approval
01Established
Formulation & Patent Protection
Proprietary platform foundation and protected intellectual property position.
02Established
In Vitro / Cellular Validation
Completed foundational cellular work informing the translational thesis.
03Active
Academic Research Protocols
Protocol development and institutional validation pathways in progress.
04Open for Partners
Clinical Trial Co-development
Seeking aligned clinical, academic, and development collaborators.
Partnership pathways
Designed for aligned co-development.
Select the track that reflects your mandate. Each pathway opens a tailored intake for focused follow-up.
Academic & research institutions
Advance independent validation through disciplined protocols and translational collaboration.
- Validation studies
- Joint protocols
- Publication pathways
Strategic capital & healthcare
Support milestone-based development and access to high-value clinical networks.
- Strategic investment
- Clinical networks
- Commercial readiness
Directional portrait placeholderScientific leadership
Dr. Phillip Moheno, PhD
President · Rapid Defense Inc.
“Progress begins with a testable hypothesis, transparent evidence, and the right institutional partners.”
Dr. Moheno leads Rapid Defense with an evidence-first philosophy: protect differentiated science, define measurable translational questions, and build partnerships capable of advancing ImmunoFolate responsibly.
PhD-led researchPlatform stewardshipInstitutional collaboration
Confidential partner access
Advance the next evidence milestone with us.
Request the executive technical preview or open a tailored discussion with Rapid Defense leadership.